Diversity In Clinical Trials

Diversity in Clinical Trials

Our vision is to be a catalyst in life science that powers greater diversity in clinical trials

Diversity in Clinical Trials Steering Committee

The mission of Medidata’s Diversity in Clinical Trials (DICT) Steering Committee is to broaden patient representation in clinical trials regardless of ethnicity, gender, geographic location or socio-economic status. Focus areas include: patient-facing initiatives, thought leadership and insights on the clinical trial diversity gap, and solutions through our products and services.

Expanding Our Patient Footprint in the Community

Lazarex Foundation

The Lazarex Cancer Foundation is a non-profit organization that helps improve patient access to clinical trials through innovative programs that provide financial assistance, education, and community outreach services. The IMPACT program seeks to transform the status quo of clinical trial recruitment and increase minority participation by providing equitable and timely access to cancer discovery for all patients. Recently, Medidata partnered with Lazarex in our Social Innovation Lab to find ways to expand its iMPACT program. Our team developed an algorithm to enable Lazarex to evaluate cancer centers across the US to find ideal partners to deploy its limited resources. Using this information, Lazarex was able to secure nearly $5 million in grants in 2019.

Tu Salud Tu Familia

Medidata is proud to sponsor Tu Salud Tu Familia (Your Health Your Family), a weekly educational program that airs on Telemundo. The show seeks to educate the Hispanic community on the value, results, and importance of different health issues, and the importance of participating in clinical trials to help develop new medications and treatments. By providing targeted health information, we continue to address and eliminate disparities throughout the Hispanic community. We are pleased to congratulate the Emerson Diversity Health Foundation on their 2020 Emmy® nomination for Health/Science - Program Feature/Segment.

Thought Leadership

Medidata experts speak about the importance of diversity in clinical trials at a variety of industry events, including SCOPE, SCRS, and more. We also convene key thought leaders from pharmaceutical companies, contract research organizations, patient advocates, and regulatory bodies (e.g. Food and Drug Administration) to highlight opportunities and solutions at Medidata NEXT events.


The Integrated Evidence worked with a variety of clinicians and researchers to leverage the power of the Medidata Triple Negative Breast Cancer (TNBC) Synthetic Control Database™, a standardized, de-identified, indication-specific, cross-sponsor, cross-trial, standardized database of hundreds of historical clinical trial patients. Our abstract on the relationship between baseline white blood cell differentiation in women of color and subsequent dose modification and outcomes was accepted for online publication at 2020 ASCO.

SCRS Partnership

Medidata is a proud sponsor of the Society for Clinical Research Sites (SCRS). SCRS was founded in 2012 in response to the growing need for an organization to represent the needs of clinical research sites on a global scale. Medidata has extensive relationships with clinical research sites around the world and is well positioned to further the mission and objective of SCRS as one of its Global Impact Partners. In 2019, Medidata became a funding sponsor of the SCRS Diversity Program, Site Awareness and Best Practices for Inclusion of Diverse Populations in Research.


Hackathon and Our Products

DICT served as the theme of the 2018 NEXT NYC Hackathon. During the 24-hour event, participants learned about the lack of representation in clinical trials. As pharmaceutical, biotech companies, contract research organizations, and tech companies worked towards a solution, that context created a sense of purpose that inspired the group.

The winning team was from Bayer HealthCare Pharmaceuticals. Their vision was to produce a real-time dashboard to track clinical trial participant demographics. In addition, by being able to share incidents, prevalence and the diversity profile, they would be able to address historical barriers impacting minority patient’s willingness to participate in trials.

Members of the Medidata DICT Steering Committee and the Bayer Hackathon team continue their work to develop a proof of concept using Medidata’s platform.